A study to test the effectiveness and safety of GSK2586184 – a new oral medicine for chronic plaque psoriasis.

Registry ID

EUCTR2012-002917-20

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

GlaxoSmithKline Research & Development Ltd

Start date

2012-12-11

Completion date

2014-03-24

Last update

2026-08-16

Conditions

• chronic plaque psoriasis

Summary

To estimate the relationship between dose of GSK2586184 and clinical response as assessed by PASI score after 12 weeks of treatment in patients with moderate to severe plaque-type psoriasis.

Locations

• , , Germany
• , , UK

View on source registry